# ADR-0001 — Aletheia as an Evidence-Governed Biomedical Discovery Platform

- **Status:** Proposed
- **Date:** 2026-10-06
- **Scope:** Platform

## Context
Biomedical discovery combines heterogeneous datasets, analytical workflows, literature, computational models, and human scientific judgment. A system that merely optimizes for candidate generation can overstate evidence or collapse observation, interpretation, and validation into one opaque process.

## Decision
Aletheia will be an **evidence-governed biomedical discovery platform**. Its primary output is not “truth” or “cure,” but traceable research objects: qualified data, reproducible analyses, evidence-linked hypotheses, explicit uncertainty, and human-reviewable decisions.

Aletheia MUST preserve source identity and provenance; distinguish computation from interpretation and validation; expose limitations and unresolved questions; record evidence both supporting and contradicting a claim; preserve human scientific authority at promotion gates; and make reproducibility artifacts first-class outputs.

Aletheia MUST NOT claim that an in-silico result alone establishes biological, clinical, or therapeutic validity.

## Consequences
The system favors slower, auditable promotion of findings over high-volume ungoverned hypothesis generation. This is intentional.

## Influences
FAIR data principles, NIH rigor/reproducibility guidance, W3C PROV, and Research Object/RO-Crate practices inform this architecture without becoming automatic scientific truth.
